Preclinical News and Research

RSS

Novel drug holds promise for treating Duchenne muscular dystrophy

A novel drug holds promise for treating Duchenne muscular dystrophy (DMD), a rare genetic disorder that causes severe muscle degeneration.

16 Dec 2024

Promising combination therapy could improve liver cancer outcomes

Dan G. Duda, DMD, PhD, of the Edwin L. Steele Laboratories for Tumor Biology and Department of Radiation Oncology at Massachusetts General Hospital, is the corresponding author of a paper published in Cancer Immunology Research, "Combination CXCR4 and PD1 Blockade Enhances Intratumoral Dendritic Cell Activation and Immune Responses Against Hepatocellular Carcinoma."

14 Dec 2024

DTI detects precancerous lesions in the pancreas

Precursor lesions of pancreatic cancer are very difficult to characterize with magnetic resonance imaging (MRI). But now, in a new study, researchers led by Noam Shemesh and Carlos Bilreiro – respectively head of the Preclinical MRI lab at Champalimaud Research and a doctor at the Champalimaud Clinical Centre's Radiology Department – have shown, for the first time, that a particular form of MRI, called Diffusion Tensor Imaging (DTI), is capable of robustly detecting pre-malignant lesions in the pancreas.

13 Dec 2024

Circadian chaos: How transportation noise harms heart health

Transportation noise poses serious risks to cardiovascular health, causing inflammation, oxidative stress, and circadian rhythm disruption, with compounded effects from air pollution.

12 Dec 2024

Insilico Medicine gets first clinical milestone payment of $10 million for XL309

Insilico Medicine ('Insilico'), a clinical-stage generative artificial intelligence (AI)-driven drug discovery and development company, today announced that it has received the first clinical milestone payment of $10 million for XL309 (previously known as ISM3091) from Exelixis.

12 Dec 2024

Long-CoV-III-21 trial shows positive results for bovhyaluronidase azoximer in post-COVID pulmonary sequelae

Petrovax announced today the positive results from "Long-CoV-III-21," a randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of bovhyaluronidase azoximer in adult patients with pulmonary sequelae of COVID-19.

12 Dec 2024

Mediterranean plants show promise for cardiovascular disease treatment

A study initiated from a final degree project at the Universitat Autònoma de Barcelona, with the involvement of researchers from the INc-UAB, the University of Barcelona and Cuban and Chilean institutions, has resulted in an exhaustive bibliographic review of a group of Mediterranean plants, whose active principles are attributed pharmacological actions in the field of cardiovascular diseases most affecting the population.

12 Dec 2024

EU-CARDIOPROTECTION efforts bring new hope for heart attack patients

Heart attacks are a leading cause of death and disability in Europe, and their effects often extend beyond the initial event, leading to chronic heart failure.

12 Dec 2024

Study uncovers brain mechanism behind empathetic responses

A specific brain mechanism modulates how animals respond empathetically to others' emotions. This is the latest finding from the research unit Genetics of Cognition, led by Francesco Papaleo, Principal Investigator at the Istituto Italiano di Tecnologia (IIT - Italian Institute of Technology) and affiliated with IRCCS Ospedale Policlinico San Martino in Genova.

12 Dec 2024